Form 4: HeartSciences CFO Granted 25,000 Performance-Based Stock Options

HeartSciences Inc. Chief Financial Officer Danielle Watson was granted 25,000 stock options with an exercise price of $4.37, vesting over three years or upon key regulatory milestones.

Summary

• Danielle Watson, Chief Financial Officer of HeartSciences Inc. (HSCS), received a grant of 25,000 stock options.
• The options have an exercise price of $4.37 per share.
• The grant was effective July 9, 2025, following approval by the Issuer's compensation committee.
• Vesting occurs over approximately three years: one-third vests on July 9, 2026 (the 12-month anniversary of the effective date), with an additional 8.333% vesting on October 9, 2026, and each successive three-month anniversary thereafter, leading to full vesting by July 9, 2028.
• Full vesting can be accelerated if the Issuer receives U.S. Food and Drug Administration (FDA) regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm, or upon a Change of Control as defined in the Reporting Person's Employment Agreement.
• As of the filing date, FDA regulatory clearance for the MyoVista wavECG device or AI-ECG algorithm has not been received.
• The options expire on July 9, 2035, ten years from the effective date, unless terminated sooner under the Issuer's 2023 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign of management alignment with long-term company goals and shareholder value creation, especially with performance-based vesting tied to critical regulatory milestones like FDA clearance. It reflects a standard compensation practice aimed at incentivizing performance.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests directly with long-term shareholder value creation.
• Performance-based vesting tied to FDA clearance for the MyoVista wavECG device or AI-ECG algorithm incentivizes the achievement of critical strategic and regulatory milestones for the company.

Negatives

• The options do not represent immediate financial gain for the CFO; their value is contingent on future stock price appreciation above the exercise price of $4.37.
• Vesting of the options is subject to the Reporting Person's continued employment with HeartSciences Inc.

Risks

• Vesting of the stock options is contingent on the Reporting Person's continued employment with HeartSciences Inc. through each applicable vesting date.
• The accelerated vesting condition, tied to U.S. FDA regulatory clearance for the MyoVista wavECG device or AI-ECG algorithm, has not yet been met as of the filing date, introducing uncertainty regarding the timing of full vesting.
• The options could expire worthless if HeartSciences Inc.'s stock price does not exceed the exercise price of $4.37 per share by the expiration date of July 9, 2035.

Future Outlook

Future vesting of the granted options is tied to continued employment and key corporate milestones, including U.S. FDA regulatory clearance for the MyoVista wavECG device or AI-ECG algorithm, or a Change of Control, indicating the company's focus on these strategic objectives.

Management Comments

• "These options were granted to the Reporting Person effective as of July 9, 2025 (the 'Effective Date'), pursuant to the approval of the compensation committee of the Issuer's board of directors."

Industry Context

The grant of performance-based stock options to a key executive like the CFO is a common practice in the healthcare technology sector, aiming to align management incentives with the achievement of critical regulatory milestones, such as FDA clearance for new medical devices or AI algorithms, which are significant value drivers in this industry.

Comparison to Industry Standards

• The structure of the option grant, including a multi-year vesting schedule and performance-based acceleration tied to regulatory approvals, is consistent with executive compensation practices in the medical device and health-tech industries, where achieving FDA clearance is a significant value driver.
• No specific comparable companies, projects, or results are detailed in the filing for direct quantitative comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Financial Officer's financial interests with shareholder value creation, particularly through the achievement of key regulatory milestones.
• Employees: This disclosure provides insight into the company's executive compensation structure and incentive programs for key personnel.

Next Steps

• Continued employment of Danielle Watson with HeartSciences Inc. to fulfill vesting conditions.
• HeartSciences Inc. pursuing and potentially achieving U.S. FDA regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm.
• Vesting of options on scheduled dates (July 9, 2026, October 9, 2026, and subsequent quarterly dates until July 9, 2028).
• Potential exercise of options by Danielle Watson upon vesting and favorable market conditions.

Key Dates

Recommendation

Keywords

HeartSciences, HSCS, stock options, executive compensation, Form 4, insider transaction, CFO, MyoVista wavECG, AI-ECG algorithm, FDA clearance, equity incentive plan